Otelixizumab
Otelixizumab
Otelixizumab (pronounced as o-te-lix-i-zu-mab) is a monoclonal antibody designed for the treatment of Type 1 diabetes. It is developed by GlaxoSmithKline and Tolerx, a biopharmaceutical company.
Etymology
The name "Otelixizumab" is derived from the Greek words "Otelixi" meaning "to tolerate" and "zumab" a common suffix for humanized antibodies.
Mechanism of Action
Otelixizumab works by binding to the CD3 receptor on T cells, which are a type of white blood cell. This binding action modulates the immune response, reducing the destruction of insulin-producing beta cells in the pancreas.
Clinical Trials
Otelixizumab has undergone several clinical trials to determine its efficacy and safety in treating Type 1 diabetes. However, the results have been mixed, with some trials showing a positive effect on preserving beta cell function, while others have shown no significant benefit.
Related Terms
- Monoclonal antibody
- Type 1 diabetes
- GlaxoSmithKline
- Tolerx
- CD3 receptor
- T cells
- Beta cells
- Clinical trials
External links
- Medical encyclopedia article on Otelixizumab
- Wikipedia's article - Otelixizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski